Dawn L Hershman1, Cathee Till2, Jason D Wright2, Danielle Awad2, Scott D Ramsey2, William E Barlow2, Lori M Minasian2, Joseph Unger2. 1. Dawn L. Hershman, Jason D. Wright, and Danielle Awad, Columbia University Medical Center, New York, NY; Cathee Till, Scott D. Ramsey, and Joseph Unger, Fred Hutchinson Cancer Research Center; William E. Barlow, University of Washington, Seattle, WA; and Lori M. Minasian, National Cancer Institute, Bethesda, MD. dlh23@columbia.edu. 2. Dawn L. Hershman, Jason D. Wright, and Danielle Awad, Columbia University Medical Center, New York, NY; Cathee Till, Scott D. Ramsey, and Joseph Unger, Fred Hutchinson Cancer Research Center; William E. Barlow, University of Washington, Seattle, WA; and Lori M. Minasian, National Cancer Institute, Bethesda, MD.
Abstract
BACKGROUND: Neuropathy is a debilitating toxicity associated with various chemotherapy agents. We evaluated the association between common comorbid conditions and the development of peripheral neuropathy in patients treated with taxane-based chemotherapy. METHODS: We examined the Southwest Oncology Group database to identify phase II and III trials that included taxane therapy from 1999 to 2011. We linked the Southwest Oncology Group clinical records to Medicare claims data according to Social Security number, sex, and date of birth. The following disease conditions potentially associated with peripheral neuropathy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases. Multivariate logistic regression was used to model the odds of experiencing grade 2 to 4 neuropathy. RESULTS: A total of 1,401 patients from 23 studies were included in the analysis. Patients receiving paclitaxel were more likely to experience grade 2 to 4 neuropathy compared with docetaxel (25% v 12%, respectively; OR, 2.20; 95% CI, 1.52 to 3.18; P < .001). The inclusion of a platinum agent was also associated with greater neuropathy (OR, 1.68; 95% CI, 1.18 to 2.40; P = .004). For each increase in age of 1 year, the odds of neuropathy increased 4% (P = .006). Patients with complications from diabetes had more than twice the odds of having neuropathy (OR, 2.13; 95% CI, 1.31 to 3.46; P = .002) compared with patients with no diabetes. In contrast, patients with autoimmune disease were half as likely to experience neuropathy (OR, 0.49; 95% CI, 0.24 to 1.02; P = .06). The other conditions were not associated with neuropathy. CONCLUSION: We found that in addition to drug-related factors, age and history of diabetes were independent predictors of the development of chemotherapy-induced peripheral neuropathy. Interestingly, we also observed that a history of autoimmune disease was associated with reduced odds of neuropathy. Patients with diabetic complications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other efficacious options exist.
BACKGROUND:Neuropathy is a debilitating toxicity associated with various chemotherapy agents. We evaluated the association between common comorbid conditions and the development of peripheral neuropathy in patients treated with taxane-based chemotherapy. METHODS: We examined the Southwest Oncology Group database to identify phase II and III trials that included taxane therapy from 1999 to 2011. We linked the Southwest Oncology Group clinical records to Medicare claims data according to Social Security number, sex, and date of birth. The following disease conditions potentially associated with peripheral neuropathy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases. Multivariate logistic regression was used to model the odds of experiencing grade 2 to 4 neuropathy. RESULTS: A total of 1,401 patients from 23 studies were included in the analysis. Patients receiving paclitaxel were more likely to experience grade 2 to 4 neuropathy compared with docetaxel (25% v 12%, respectively; OR, 2.20; 95% CI, 1.52 to 3.18; P < .001). The inclusion of a platinum agent was also associated with greater neuropathy (OR, 1.68; 95% CI, 1.18 to 2.40; P = .004). For each increase in age of 1 year, the odds of neuropathy increased 4% (P = .006). Patients with complications from diabetes had more than twice the odds of having neuropathy (OR, 2.13; 95% CI, 1.31 to 3.46; P = .002) compared with patients with no diabetes. In contrast, patients with autoimmune disease were half as likely to experience neuropathy (OR, 0.49; 95% CI, 0.24 to 1.02; P = .06). The other conditions were not associated with neuropathy. CONCLUSION: We found that in addition to drug-related factors, age and history of diabetes were independent predictors of the development of chemotherapy-induced peripheral neuropathy. Interestingly, we also observed that a history of autoimmune disease was associated with reduced odds of neuropathy. Patients with diabetic complications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other efficacious options exist.
Authors: Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: Dawn L Hershman; Louis H Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; Deborah Fuentes; Danielle Awad; Katherine D Crew Journal: Breast Cancer Res Treat Date: 2010-12-03 Impact factor: 4.872
Authors: Mohamed Naguib; Jijun J Xu; Philippe Diaz; David L Brown; David Cogdell; Bihua Bie; Jianhua Hu; Suzanne Craig; Walter N Hittelman Journal: Anesth Analg Date: 2012-03-05 Impact factor: 5.108
Authors: Bryan P Schneider; Lang Li; Milan Radovich; Tatiana Foroud; George W Sledge; Fei Shen; Kathy D Miller; David A Flockhart; Guanglong Jiang; Gail Vance; Laura Gardner; Matteo Vatta; Shaochun Bai; Dongbing Lai; Daniel Koller; Fengmin Zhao; Anne O'Neill; Mary Lou Smith; Elda Railey; Carol White; Ann Partridge; Joseph Sparano; Nancy E Davidson Journal: Clin Cancer Res Date: 2015-07-02 Impact factor: 12.531
Authors: Abraham C J Stork; Bart C Jacobs; Anne P Tio-Gillen; Marijke Eurelings; Marc D Jansen; Leonard H van den Berg; Nicolette C Notermans; W-Ludo van der Pol Journal: J Neuroimmunol Date: 2014-01-29 Impact factor: 3.478
Authors: E K Rowinsky; V Chaudhry; A A Forastiere; S E Sartorius; D S Ettinger; L B Grochow; B G Lubejko; D R Cornblath; R C Donehower Journal: J Clin Oncol Date: 1993-10 Impact factor: 44.544
Authors: Daniel L Hertz; Kelley M Kidwell; Kiran Vangipuram; Feng Li; Manjunath P Pai; Monika Burness; Jennifer J Griggs; Anne F Schott; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry Journal: Clin Cancer Res Date: 2018-04-27 Impact factor: 12.531
Authors: Alexandre Chan; Daniel L Hertz; Manuel Morales; Elizabeth J Adams; Sharon Gordon; Chia Jie Tan; Nathan P Staff; Jayesh Kamath; Jeong Oh; Shivani Shinde; Doreen Pon; Niharkia Dixit; James D'Olimpio; Cristina Dumitrescu; Margherita Gobbo; Kord Kober; Samantha Mayo; Linda Pang; Ishwaria Subbiah; Andreas S Beutler; Katherine B Peters; Charles Loprinzi; Maryam B Lustberg Journal: Support Care Cancer Date: 2019-07-30 Impact factor: 3.603
Authors: Hanna Bandos; Joy Melnikow; Donna R Rivera; Sandra M Swain; Keren Sturtz; Louis Fehrenbacher; James L Wade; Adam M Brufsky; Thomas B Julian; Richard G Margolese; Edward C McCarron; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: M Eileen Dolan; Omar El Charif; Heather E Wheeler; Eric R Gamazon; Shirin Ardeshir-Rouhani-Fard; Patrick Monahan; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Chunkit Fung; Jeri Kim; Sophie D Fossa; Daniel L Hertz; Taisei Mushiroda; Michiaki Kubo; Lawrence H Einhorn; Nancy J Cox; Lois B Travis Journal: Clin Cancer Res Date: 2017-06-13 Impact factor: 12.531
Authors: Christine Miaskowski; Judy Mastick; Steven M Paul; Kimberly Topp; Betty Smoot; Gary Abrams; Lee-May Chen; Kord M Kober; Yvette P Conley; Margaret Chesney; Kay Bolla; Grace Mausisa; Melissa Mazor; Melisa Wong; Mark Schumacher; Jon D Levine Journal: J Pain Symptom Manage Date: 2017-01-04 Impact factor: 3.612
Authors: Dawn L Hershman; Joseph M Unger; Katherine D Crew; Cathee Till; Heather Greenlee; Lori M Minasian; Carol M Moinpour; Danika L Lew; Louis Fehrenbacher; James L Wade; Siu-Fun Wong; Michael J Fisch; N Lynn Henry; Kathy S Albain Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Gary R Zirpoli; Susan E McCann; Lara E Sucheston-Campbell; Dawn L Hershman; Gregory Ciupak; Warren Davis; Joseph M Unger; Halle C F Moore; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; G Thomas Budd; Kathy S Albain; Christine B Ambrosone Journal: J Natl Cancer Inst Date: 2017-12-01 Impact factor: 13.506